Accuracy of Self-Checked Fecal Occult Blood Testing for Colorectal Cancer in Thai Patients

  • Lohsiriwat, Varut (Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University)
  • Published : 2014.10.11


Purpose: Colorectal cancer (CRC) screening with fecal occult blood testing (FOBT) has been associated with a reduction in CRC incidence and CRC-related mortality. However, a conventional FOBT requires stool collection and handling, which may be inconvenient for participants. The EZ-Detect$^{TM}$ (Siam Pharmaceutical Thailand) is a FDA-approved chromogen-substrate based FOBT which is basically a self-checked FOBT (no stool handling required). This study aimed to evaluate the accuracy of EZ-Detect for CRC detection. Methods: This prospective study was conducted in the Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand between November 2013 and May 2014. Some 96 patients with histologically-proven CRC and 101 patients with normal colonoscopic findings were invited to perform self-checked FOBT according to the manufacturer's instructions. Results were compared with endoscopic and pathologic findings. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for CRC detection were calculated. Results: The present study revealed the sensitivity, specificity, PPV and NPV of this self-checked FOBT for CRC detection to be 41% (95% CI: 31-51), 97% (95% CI: 92-99), 93% (95% CI: 81-98) and 63% (95% CI: 55-70), respectively. The overall accuracy of the self-checked FOBT for identifying CRC was 70%. The sensitivity for CRC detection based on 7th AJCC staging was 29% for stage I, 32% for stage II and 50% for stage III/IV (P=0.19). The sensitivity was 33% for proximal colon and 42% for distal colon and rectal cancer (P=0.76). Notably, none of nine infiltrative lesions gave a positive FOBT. Conclusions: The self-checked FOBT had an acceptable accuracy of CRC detection except for infiltrative tumors. This home-administrated or 'DIY' do-it-yourself FOBT could be considered as one non-invasive and convenient tool for CRC screening.


  1. Halloran SP, Launoy G, Zappa M (2012). European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition-Faecal occult blood testing. Endoscopy, 44, 65-87.
  2. Brouse CH, Basch CE, Wolf RL, et al (2003). Barriers to colorectal cancer screening with fecal occult blood testing in a predominantly minority urban population: a qualitative study. Am J Public Health, 93, 1268-71.
  3. Cruz-Correa M, Schultz K, Jagannath S, et al (2007). Performance characteristics and comparison of two fecal occult blood tests in patients undergoing colonoscopy. Dig Dis Sci, 52, 1009-13.
  4. DeBourcy AC, Lichtenberger S, Felton S, et al (2008). Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med, 23, 169-74.
  5. Haug U, Knudsen AB, Brenner H, Kuntz KM (2011). Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn, 11, 605-16.
  6. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2007). Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev, CD001216.
  7. Hou SI, Chen PH (2004). Home-administered fecal occult blood test for colorectal cancer screening among worksites in Taiwan. Prev Med, 38, 78-84.
  8. Hynam KA, Hart AR, Gay SP, et al (1995). Screening for colorectal cancer: reasons for refusal of faecal occult blood testing in a general practice in England. J Epidemiol Community Health, 49, 84-6.
  9. Jones RM, Woolf SH, Cunningham TD, et al (2010). The relative importance of patient-reported barriers to colorectal cancer screening. Am J Prev Med, 38, 499-507.
  10. Logan RF, Patnick J, Nickerson C, et al (2012). Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut, 61, 1439-46.
  11. Katicic M, Antoljak N, Kujundzic M, et al (2012). Results of National Colorectal Cancer Screening Program in Croatia (2007-2011). World J Gastroenterol, 18, 4300-7.
  12. Khuhaprema T, Srivatanakul P (2008). Colon and rectum cancer in Thailand: an overview. Jpn J Clin Oncol, 38, 237-43.
  13. Lansdorp-Vogelaar I, Knudsen AB, Brenner H (2011). Costeffectiveness of colorectal cancer screening. Epidemiol Rev, 33, 88-100.
  14. Lohsiriwat V, Lohsiriwat D, Thavichaigarn P (2009). Colorectal cancer screening and surveillance: a survey among Thai general surgeons. Asian Pac J Cancer Prev, 10, 467-70.
  15. Lohsiriwat V, Thavichaigarn P, Awapittaya B (2007). A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection. J Med Assoc Thai, 90, 2291-5.
  16. Lowenfels AB (2002). Fecal occult blood testing as a screening procedure for colorectal cancer. Ann Oncol, 13, 40-3.
  17. Mosli MH, Al-Ahwal MS (2012). Colorectal cancer in the Kingdom of Saudi Arabia: need for screening. Asian Pac J Cancer Prev, 13, 3809-13.
  18. Nakazato M, Yamano HO, Matsushita HO, et al (2006). Immunologic fecal occult blood test for colorectal cancer screening. JMAJ, 49, 203-7.
  19. Norwati D, Harmy MY, Norhayati MN, Amry AR (2014). Colorectal cancer screening practices of primary care providers: results of a national survey in
  20. Tate JJ, Northway J, Royle GT, Taylor I (1989). Evaluation of a 'DIY' test for the detection of colorectal cancer. J R Soc Med, 82, 388-90.
  21. Park DI, Ryu S, Kim YH, et al (2010). Comparison of guaiacbased and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol, 105, 2017-25.
  22. Rex DK, Johnson DA, Anderson JC, et al (2009). American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol, 104, 739-50.
  23. Shin A, Choi KS, Jun JK, et al (2013). Validity of fecal occult blood test in the national cancer screening program, Korea. PLoS One, 8, 79292.
  24. Strul H, Arber N (2002). Fecal occult blood test for colorectal cancer screening. Ann Oncol, 13, 51-6.
  25. Tibble J, Sigthorsson G, Foster R, et al (2001). Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut, 49, 402-8.
  26. Zavoral M, Suchanek S, Majek O, et al (2014). Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol, 20, 3825-34.

Cited by

  1. High prevalence of advanced colorectal neoplasia in the Thai population: a prospective screening colonoscopy of 1,404 cases vol.16, pp.1, 2016,